Patent expiries set to boost flagging French biosimilar market
This article was originally published in Scrip
Sales of biosimilars in France grew 11-fold between 2008 and 2012, but in value terms the market remains small, with sales of just €60m last year. However, this is set to change as major drugs such as Roche's MabThera (rituximab) and AbbVie's Humira (adalimumab) lose patent protection in the next few years, resulting in an increase in biosimilars' market share and a concomitant decline in the prices of reference drugs, according to a report from the regulatory agency ANSM.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.